The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.

@article{Yang2007TheSH,
  title={The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.},
  author={Yang Yang and Veronica Macleod and Yuemeng Dai and Yekaterina Khotskaya-Sample and Zachary H. Shriver and Ganesh Venkataraman and Ram Sasisekharan and Annamaria Naggi and Giangiacomo Torri and Benito Casu and Israel Vlodavsky and Larry J. Suva and Joshua Epstein and Shmuel Yaccoby and John D. Shaughnessy and Bart Barlogie and Ralph D. Sanderson},
  journal={Blood},
  year={2007},
  volume={110 6},
  pages={2041-8}
}
The heparan sulfate proteoglycan syndecan-1 is expressed by myeloma cells and shed into the myeloma microenvironment. High levels of shed syndecan-1 in myeloma patient sera correlate with poor prognosis and studies in animal models indicate that shed syndecan-1 is a potent stimulator of myeloma tumor growth and metastasis. Overexpression of extracellular endosulfatases, enzymes which remove 6-O sulfate groups from heparan sulfate chains, diminishes myeloma tumor growth in vivo. Together, these… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 58 references

Similar Papers

Loading similar papers…